134 related articles for article (PubMed ID: 16842980)
1. ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004.
Montgomery SA; van Zwieten-Boot B
Eur Neuropsychopharmacol; 2007 Jan; 17(1):70-7. PubMed ID: 16842980
[No Abstract] [Full Text] [Related]
2. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
Green MF; Nuechterlein KH; Gold JM; Barch DM; Cohen J; Essock S; Fenton WS; Frese F; Goldberg TE; Heaton RK; Keefe RS; Kern RS; Kraemer H; Stover E; Weinberger DR; Zalcman S; Marder SR
Biol Psychiatry; 2004 Sep; 56(5):301-7. PubMed ID: 15336511
[TBL] [Abstract][Full Text] [Related]
3. [Interdependence of positive, negative and depressive symptoms in the course of schizophrenia without psychotic antecedents].
d'Amato T; Dumas P; Saoud M; Mandran M
Encephale; 1999 Nov; 25 Spec No 4():25-8. PubMed ID: 10609107
[No Abstract] [Full Text] [Related]
4. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
Buchanan RW; Davis M; Goff D; Green MF; Keefe RS; Leon AC; Nuechterlein KH; Laughren T; Levin R; Stover E; Fenton W; Marder SR
Schizophr Bull; 2005 Jan; 31(1):5-19. PubMed ID: 15888422
[TBL] [Abstract][Full Text] [Related]
5. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder.
Green MF
J Clin Psychiatry; 2006 Oct; 67(10):e12. PubMed ID: 17107235
[TBL] [Abstract][Full Text] [Related]
6. Functional outcomes in schizophrenia.
McEvoy JP
J Clin Psychiatry; 2008; 69 Suppl 3():20-4. PubMed ID: 18533758
[TBL] [Abstract][Full Text] [Related]
7. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
8. Schizophrenia and the immediacy mechanism.
Salzinger K
Am Psychol; 2006 Jan; 61(1):74-5. PubMed ID: 16435981
[No Abstract] [Full Text] [Related]
9. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
[TBL] [Abstract][Full Text] [Related]
10. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
[TBL] [Abstract][Full Text] [Related]
11. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
[TBL] [Abstract][Full Text] [Related]
12. Does operational diagnosis of schizophrenia significantly impact intellectual deficits in psychotic disorders?
Kitamura H; Shioiri T; Itoh M; Sato Y; Shichiri K; Someya T
J Intellect Disabil Res; 2007 Oct; 51(Pt 10):812-20. PubMed ID: 17803499
[TBL] [Abstract][Full Text] [Related]
13. Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia.
Cho RY; Ford JM; Krystal JH; Laruelle M; Cuthbert B; Carter CS
Schizophr Bull; 2005 Oct; 31(4):865-9. PubMed ID: 16166611
[TBL] [Abstract][Full Text] [Related]
14. ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder.
Montgomery SA; Lecrubier Y; Baldwin DS; Kasper S; Lader M; Nil R; Stein D; Van Ree JM;
Eur Neuropsychopharmacol; 2004 Oct; 14(5):425-33. PubMed ID: 15336305
[No Abstract] [Full Text] [Related]
15. [Neuropsychological disorders in multiple sclerosis].
Greim B; Zettl UK
Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S28-31. PubMed ID: 19685387
[TBL] [Abstract][Full Text] [Related]
16. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia.
Savilla K; Kettler L; Galletly C
Aust N Z J Psychiatry; 2008 Jun; 42(6):496-504. PubMed ID: 18465376
[TBL] [Abstract][Full Text] [Related]
17. [Cognitive deficits in schizophrenia and other psychotic disorders].
Fagerlund B; Glenthøj BY
Ugeskr Laeger; 2008 Nov; 170(46):3770-2. PubMed ID: 19014728
[TBL] [Abstract][Full Text] [Related]
18. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
19. Course of cognitive symptoms in schizophrenia: a review of the literature.
Ojeda N; Sánchez P; Elizagárate E; Yöller AB; Ezcurra J; Ramírez I; Ballesteros J
Actas Esp Psiquiatr; 2007; 35(4):263-70. PubMed ID: 17592790
[TBL] [Abstract][Full Text] [Related]
20. [Schizophrenic disorders--does cognitive dysfunction relate to characteristics of course and psychopathology of the illness?].
Wciórka J; Bembenek A; Hintze B; Kühn-Dymecka A
Psychiatr Pol; 2006; 40(5):867-84. PubMed ID: 17217232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
